FENNEC PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
FENNEC PHARMACEUTICALS INC. (FENC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 370.00 thousand shares for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2023-11-09
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-09-30 was 370.00K shares, a 19.35% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-06-30 was 125.00K shares, a 59.02% decline year-over-year.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-03-31 was 580.00K shares, a 190.00% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2022-09-30 was 310.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month |
|---|---|---|---|
| 2023-09-30 | 370.00K shares 10-Q · filed 2023-11-09 | 495.00K shares derived: sum of 2 quarters · filed 2023-11-09 | 1.07M shares derived: sum of 3 quarters · filed 2023-11-09 |
| 2023-06-30 | 125.00K shares 10-Q · filed 2023-11-09 | 705.00K shares derived: sum of 2 quarters · filed 2023-11-09 | |
| 2023-03-31 | 580.00K shares 10-Q · filed 2023-11-09 | ||
| 2022-09-30 | 310.00K shares 10-Q · filed 2022-11-14 | 615.00K shares derived: sum of 2 quarters · filed 2022-11-14 | 815.00K shares derived: sum of 3 quarters · filed 2022-11-14 |
| 2022-06-30 | 305.00K shares 10-Q · filed 2022-11-14 | 505.00K shares derived: sum of 2 quarters · filed 2022-11-14 | |
| 2022-03-31 | 200.00K shares 10-Q · filed 2022-11-14 | ||
| 2014-09-30 | 503.00K shares 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |